$25.00
+0.020%Avanos Medical, Inc., a medical technology company, focuses on delivering medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions; and respiratory health products, such as closed airway suction systems and other airway management devices under the Ballard, Microcuff, and Endoclear brands. The company also provides a portfolio of non-opioid pain solutions, including acute pain products, such as On-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems; and interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
Negative free cash flow despite positive earnings raises concerns about cash generation ability or heavy capital requirements.
Capital-intensive operations require significant reinvestment. Monitor whether CapEx is maintenance or growth-oriented.
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Deteriorating cash generation: Both declining FCF and weak conversion rate signal fundamental challenges. Investigate margin pressure, rising costs, or working capital issues.
AVNS โข NYSE
| Avanos Medical, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||||||||||
-72.9M | -392.1M | -61.8M | 50.5M | 5.2M | -27.2M | -45.9M | 57.5M | 79.3M | 39.8M | -426.3M | 27.1M | 154.6M | 152.6M | 142.4M | |
38.9M | 45.5M | 46.1M | 47.7M | 38.3M | 42.9M | 36.9M | 33.5M | 59.5M | 65.2M | 65.4M | 85.4M | 69.2M | 57.6M | 51.1M | |
0.0 | 0.0 | 0.0 | 0.0 | -3.4M | 25.9M | -6.5M | 3.7M | -6.2M | -11.5M | 8.2M | -35M | -900K | -11.6M | 3.5M | |
0.0 | 13.8M | 15.8M | 15.9M | 13.2M | 12.1M | 10.5M | 10.5M | 12.6M | 14.8M | 14.1M | 7.9M | 6M | 5.3M | 2.6M | |
98.9M | 398.5M | 50.3M | 1.1M | 8M | 11.6M | -9.9M | -107.4M | 3.3M | -11.1M | 453.2M | 49.7M | 6.8M | -10.9M | 8.3M | |
(14.1M) | (3.3M) | (23.6M) | (0.0) | (0.0) | (0.0) | (8.4M) | (96.6M) | (21.4M) | (29.1M) | -43.3M | (87.6M) | (74.2M) | (94.3M) | (0.0) | |
9.8M | 35M | -18M | -24.3M | 26M | -67.8M | -59.6M | -143.4M | -4.3M | 91.6M | -17M | 12.8M | -11.9M | 9.6M | -68.3M | |
74.7M | 100.7M | 32.4M | 90.9M | 87.3M | -2.5M | -74.5M | -145.6M | 144.2M | 188.8M | 97.6M | 147.9M | 223.8M | 202.6M | 139.6M | |
INVESTING ACTIVITIES | |||||||||||||||
-31.6M | -17.8M | -17.8M | -19.3M | -21M | -20.2M | -50.6M | -49.1M | -43.2M | -29.1M | -70.4M | -78.5M | -49M | -40.8M | -39.7M | |
-28M | -9.7M | (39.4M) | -116.1M | (0.0) | -4M | -57.5M | (688.6M) | (100K) | -175M | (7.8M) | (0.0) | -2.2M | (0.0) | -3.7M | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -2.2M | (0.0) | (0.0) | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 49M | 0.0 | 0.0 | |
-1M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 754.3M | 100K | 3.2M | 7.8M | 7.8M | -46.5M | 500K | 3.9M | |
-60.6M | -27.5M | (21.6M) | -135.4M | -21M | -24.2M | -108.1M | (639.5M) | -43.1M | -200.9M | -62.6M | -70.7M | -50.9M | -40.3M | -39.5M | |
FINANCING ACTIVITIES | |||||||||||||||
-2.6M | -12.8M | -19.1M | -45.5M | -11.5M | -900K | -3.6M | -900K | -2.5M | -900K | -1M | 0.0 | 0.0 | 0.0 | 0.0 | |
-34.4M | -33.6M | -64.7M | 103.4M | -50M | -69.8M | -200K | -339M | 0.0 | -900K | -51M | 624.2M | -63.9M | -24.1M | 11.8M | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -680M | (0.0) | (0.0) | (0.0) | |
-3.3M | -12.8M | -19.1M | -45.5M | -11.5M | -900K | -3.6M | -900K | -2.5M | -900K | -1M | (0.0) | (0.0) | (0.0) | (0.0) | |
0.0 | -2.7M | -10.4M | -1.2M | 6.2M | 700K | 5.3M | 15.5M | 4.7M | 400K | 1.4M | -595M | -116.1M | -109.8M | -126.9M | |
-37M | -49.1M | -94.2M | 56.7M | -55.3M | -70M | 1.5M | -324.4M | 2.2M | -1.4M | -50.6M | 29.2M | -180M | -133.9M | -115.1M | |
CASH FLOW SUMMARY | |||||||||||||||
5M | -4.1M | 200K | -3M | -4M | 2.9M | 1.9M | -4.7M | 2.7M | -2.3M | -3.9M | -1.5M | 3.3M | -600K | 800K | |
-17.9M | 20M | -40M | 9.2M | 7M | -93.8M | -179.2M | 164.8M | 106M | -15.8M | -19.5M | 104.9M | -3.8M | 27.8M | -14.2M | |
107.7M | 87.7M | 127.7M | 118.5M | 111.5M | 205.3M | 384.5M | 219.7M | 113.7M | 129.5M | 149M | 44.1M | 47.9M | 20.1M | 34.3M | |
89.8M | 107.7M | 87.7M | 127.7M | 118.5M | 111.5M | 205.3M | 384.5M | 219.7M | 113.7M | 129.5M | 149M | 44.1M | 47.9M | 20.1M | |
43.1M | 82.9M | 14.6M | 71.6M | 66.3M | -22.7M | -125.1M | -194.7M | 101M | 159.7M | 27.2M | 69.4M | 174.8M | 161.8M | 99.9M |
AVNS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 05, 2026 | May 05, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 05, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 14, 2026 | April 13, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 12, 2026 | March 06, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | March 12, 2026 | April 21, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 25, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 24, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 24, 2026 | February 24, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 13, 2026 | January 13, 2026 | 2026 | |
8-K/A 8-K/A 2025 (Amended) N/A | December 05, 2025 | October 21, 2025 | 2025 |
Continue your AVNS research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.